$ニューロボ ファーマシューティカルズ(NRBO.US)$ NEWS NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
Groundbreaking Progress in Obesity Treatment: NeuroBo Pharmaceuticals Receives FDA Clearance for Clinical Trial of DA-1726. In a significant milestone for obesity treatment, NeuroBo Pharmaceuticals, a leading pharmaceutical company, has received FDA clearance to commence a Phase 1 clinical trial for its new drug candidate, DA-1726. This marks a critical advancement in the medical field, with potential far-reaching implicati...
$ニューロボ ファーマシューティカルズ(NRBO.US)$NeuroBo Pharmaceuticals Receives First Site IRB Approval For Its Phase 1 Clinical Trial Evaluating DA-1726 For Treatment Of Obesity
10
報告
Jaguar8 :
And of course they will buy this one even if it’s just Phase 1 which has not even started
ニューロボ ファーマシューティカルズに関するコメント
NEWS
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
In a significant milestone for obesity treatment, NeuroBo Pharmaceuticals, a leading pharmaceutical company, has received FDA clearance to commence a Phase 1 clinical trial for its new drug candidate, DA-1726. This marks a critical advancement in the medical field, with potential far-reaching implicati...
time to load up
まだコメントはありません